Our Vision

Our vision is to offer patients improved outcomes and better quality of life across a range of clinical conditions through the application of our next generation soft tissue radiofrequency ablation (RFA) technology.

The use of radiofrequency ablation is now an established non-surgical minimally invasive procedure to treat soft tissue tumours, fibroids and other related conditions. Our technology, Bimodal Electric Tissue Ablation, or BETA for short, is an enhanced form of tissue ablation whereby abnormal tissues can be destroyed in situ, as an alternative to surgery. Standard RFA has limitations in terms of the size of tumours or fibroids it can address, but BETA can improve upon these, potentially allowing the ablation of previously untreatable tumours and fibroids and protecting healthy tissue.

The company was founded in 2015 and was the first spin-out from the Norfolk and Norwich University Hospital NHS Foundation Trust, where the BETA technology was invented.

Ablatus has been certified to ISO 13485:2016 following successful audits with BSI. ISO 13485 is a global standard in quality management systems for medical devices that supports polices and processes across the entire business.